Hanno M Specht1, Kerstin A Kessel1,2, Markus Oechsner1, Bernhard Meyer3, Claus Zimmer4,5, Stephanie E Combs6,7,8. 1. Klinik für RadioOnkologie und Strahlentherapie, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, Munich, Germany. 2. Institut für Innovative Radiotherapie, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Oberschleißheim, Germany. 3. Neurochirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, 81675, Munich, Germany. 4. Abteilung Neuroradiologie, Klinikum rechts der Isar, Technische Universität München, 81675, Munich, Germany. 5. Deutsches Konsortium für Translationale Krebsforschung, Technische Universität München, 81675, Munich, Germany. 6. Klinik für RadioOnkologie und Strahlentherapie, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, Munich, Germany. Stephanie.Combs@tum.de. 7. Institut für Innovative Radiotherapie, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Oberschleißheim, Germany. Stephanie.Combs@tum.de. 8. Deutsches Konsortium für Translationale Krebsforschung, Technische Universität München, 81675, Munich, Germany. Stephanie.Combs@tum.de.
Abstract
PURPOSE: Aim of this single center, retrospective study was to assess the efficacy and safety of linear accelerator-based hypofractionated stereotactic radiotherapy (HFSRT) to the resection cavity of brain metastases after surgical resection. Local control (LC), locoregional control (LRC = new brain metastases outside of the treatment volume), overall survival (OS) as well as acute and late toxicity were evaluated. PATIENTS AND METHODS: 46 patients with large (> 3 cm) or symptomatic brain metastases were treated with HFSRT. Median resection cavity volume was 14.16 cm(3) (range 1.44-38.68 cm(3)) and median planning target volume (PTV) was 26.19 cm(3) (range 3.45-63.97 cm(3)). Patients were treated with 35 Gy in 7 fractions prescribed to the 95-100 % isodose line in a stereotactic treatment setup. LC and LRC were assessed by follow-up magnetic resonance imaging. RESULTS: The 1-year LC rate was 88 % and LRC was 48 %; 57% of all patients showed cranial progression after HFSRT (4% local, 44% locoregional, 9% local and locoregional). The median follow-up was 19 months; median OS for the whole cohort was 25 months. Tumor histology and recursive partitioning analysis score were significant predictors for OS. HFSRT was tolerated well without any severe acute side effects > grade 2 according to CTCAE criteria. CONCLUSION: HFSRT after surgical resection of brain metastases was tolerated well without any severe acute side effects and led to excellent LC and a favorable OS. Since more than half of the patients showed cranial progression after local irradiation of the resection cavity, close patient follow-up is warranted. A prospective evaluation in clinical trials is currently being performed.
PURPOSE: Aim of this single center, retrospective study was to assess the efficacy and safety of linear accelerator-based hypofractionated stereotactic radiotherapy (HFSRT) to the resection cavity of brain metastases after surgical resection. Local control (LC), locoregional control (LRC = new brain metastases outside of the treatment volume), overall survival (OS) as well as acute and late toxicity were evaluated. PATIENTS AND METHODS: 46 patients with large (> 3 cm) or symptomatic brain metastases were treated with HFSRT. Median resection cavity volume was 14.16 cm(3) (range 1.44-38.68 cm(3)) and median planning target volume (PTV) was 26.19 cm(3) (range 3.45-63.97 cm(3)). Patients were treated with 35 Gy in 7 fractions prescribed to the 95-100 % isodose line in a stereotactic treatment setup. LC and LRC were assessed by follow-up magnetic resonance imaging. RESULTS: The 1-year LC rate was 88 % and LRC was 48 %; 57% of all patients showed cranial progression after HFSRT (4% local, 44% locoregional, 9% local and locoregional). The median follow-up was 19 months; median OS for the whole cohort was 25 months. Tumor histology and recursive partitioning analysis score were significant predictors for OS. HFSRT was tolerated well without any severe acute side effects > grade 2 according to CTCAE criteria. CONCLUSION: HFSRT after surgical resection of brain metastases was tolerated well without any severe acute side effects and led to excellent LC and a favorable OS. Since more than half of the patients showed cranial progression after local irradiation of the resection cavity, close patient follow-up is warranted. A prospective evaluation in clinical trials is currently being performed.
Authors: Bree R Eaton; Michael J LaRiviere; Michael J La Riviere; Sungjin Kim; Roshan S Prabhu; Kirtesh Patel; Shravan Kandula; Nelson Oyesiku; Jeffrey Olson; Walter Curran; Hui-Kuo Shu; Ian Crocker Journal: J Neurooncol Date: 2015-04-11 Impact factor: 4.130
Authors: Hideki Ogiwara; Kapila Kalakota; Sunpreet S Rakhra; Irene B Helenowski; Maryanne H Marymont; John A Kalapurakal; Minesh P Mehta; Robert B Levy; James P Chandler Journal: J Neurooncol Date: 2012-03-18 Impact factor: 4.130
Authors: Cameron Brennan; T Jonathan Yang; Patrick Hilden; Zhigang Zhang; Kelvin Chan; Yoshiya Yamada; Timothy A Chan; Stella C Lymberis; Ashwatha Narayana; Viviane Tabar; Philip H Gutin; Åse Ballangrud; Eric Lis; Kathryn Beal Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-01 Impact factor: 7.038
Authors: Martin Kocher; Andrea Wittig; Marc Dieter Piroth; Harald Treuer; Heinrich Seegenschmiedt; Maximilian Ruge; Anca-Ligia Grosu; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-04-09 Impact factor: 3.621
Authors: David Mathieu; Douglas Kondziolka; John C Flickinger; David Fortin; Brendan Kenny; Karine Michaud; Sanjay Mongia; Ajay Niranjan; L Dade Lunsford Journal: Neurosurgery Date: 2008-04 Impact factor: 4.654
Authors: Neal Luther; Douglas Kondziolka; Hideyuki Kano; Seyed H Mousavi; Johnathan A Engh; Ajay Niranjan; John C Flickinger; L Dade Lunsford Journal: Neurosurgery Date: 2013-12 Impact factor: 4.654
Authors: Ahmad Walid Ayas; Stefan Grau; Karolina Jablonska; Daniel Ruess; Maximilian Ruge; Simone Marnitz; Roland Goldbrunner; Martin Kocher Journal: Strahlenther Onkol Date: 2018-09-14 Impact factor: 3.621
Authors: S Grau; M Herling; C Mauch; N Galldiks; H Golla; M Schlamann; A H Scheel; E Celik; M Ruge; R Goldbrunner Journal: Chirurg Date: 2021-01-27 Impact factor: 0.955
Authors: S Rogers; A Stauffer; N Lomax; S Alonso; B Eberle; S Gomez Ordoñez; T Lazeroms; E Kessler; M Brendel; L Schwyzer; O Riesterer Journal: J Neurooncol Date: 2021-09-21 Impact factor: 4.130
Authors: Maximilian J Schwendner; Nico Sollmann; Christian D Diehl; Markus Oechsner; Bernhard Meyer; Sandro M Krieg; Stephanie E Combs Journal: Front Oncol Date: 2018-10-02 Impact factor: 6.244